<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02678533</url>
  </required_header>
  <id_info>
    <org_study_id>P130103</org_study_id>
    <secondary_id>2014-005264-14</secondary_id>
    <nct_id>NCT02678533</nct_id>
  </id_info>
  <brief_title>Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and Plerixafor</brief_title>
  <acronym>FancoMob</acronym>
  <official_title>Pilot Study Assessing the Feasibility of CD34+ Cells Mobilization and Collection After Treatment With G-CSF and Plerixafor in Patients With Fanconi Anemia for Subsequent Treatment by Gene Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EuroFancolen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the feasibility of Plerixafor used in combination with&#xD;
      G-CSF (Granulocyte Colony Stimulating Factor) in 5 Fanconi anemia patients to mobilize and&#xD;
      collect a sufficient number of peripheral blood CD34+ cells for peripheral blood apheresis,&#xD;
      for further gene therapy study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fanconi anemia is an autosomal recessive disease with an average survival of around 24 years&#xD;
      old. The number of cells producted by bone marrow decreases around 5-10 years old.&#xD;
      Hematological symptoms occur around 7 years old. 80% of patients with Fanconi anemia have&#xD;
      clinical signs of bone marrow failure in the first decade of life. Generally macrocytosis is&#xD;
      the first noticeable sign. Then it leads to thrombocytopenia, anemia and pancytopenia.&#xD;
&#xD;
      Epidemiologic studies show that nearly all of the patients will have medullar aplasia before&#xD;
      40 years old, which is then the first cause of mortality.&#xD;
&#xD;
      It must be emphasized that these complications may occur simultaneously for the same patient,&#xD;
      so joint therapeutic intervention is needed.&#xD;
&#xD;
      There is no basic treatment. Some currently used treatments cure cytopenias. These treatments&#xD;
      involve blood transfusion, oral androgen, hematopoietic growth factor administration, such as&#xD;
      Epo and G-CSF to treat anemia and neutropenia. These treatments are not curative.&#xD;
      Hematopoietic stem cell transplantation is the only treatment able to restore permanently&#xD;
      hematopoiesis. However, this treatment leads to a high level risk of developing solid tumors&#xD;
      and other complications.&#xD;
&#xD;
      All these data justify of developing a stem cells gene therapy treatment using a lentiviral&#xD;
      vector expressing wild-type FANCA gene under CIBER promoter.&#xD;
&#xD;
      Three studies have shown the potential number of cells to be mobilized in patients with&#xD;
      Fanconi anemia.&#xD;
&#xD;
      The aim is first, to show if administering G-CSF with plerixafor may lead to collect enough&#xD;
      cells to potentially perform a gene therapy graft. Secondly the study will assess the&#xD;
      tolerance, the stem cells' mobilization kinetic and collected cells' biological features.&#xD;
&#xD;
      This study will be performed in Necker Children Hospital. 8 patients will be enrolled in&#xD;
      order to reach 5 treated patients and to analyse how many injections and days are required to&#xD;
      reach the cells' number goal.&#xD;
&#xD;
      Sequential blood samples of patients will be drawn to monitor complete blood count (CBC),&#xD;
      platelet, CD34+ cells rate and stem cells phenotype.&#xD;
&#xD;
      The clinical and biological data will be anonymously entered in a electronic case report by&#xD;
      the investigators up to the end of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 10, 2017</start_date>
  <completion_date type="Actual">May 3, 2019</completion_date>
  <primary_completion_date type="Actual">November 20, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>level of CD34+ cells mobilization</measure>
    <time_frame>from day 5 to day 8 after the first injection of G-CSF</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of treatment-related adverse events as a measure of tolerability</measure>
    <time_frame>30 days after cytapheresis</time_frame>
    <description>Occurrence of adverse effect due to G-CSF and plerixafor administration</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Fanconi Anemia</condition>
  <arm_group>
    <arm_group_label>Fanconi anemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G-CSF and Plerixafor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>D1 to D4 : Injection of 12 µg/kg of G-CSF twice a day . D5 : injection of 12 µg/kg of G-CSF (once/ twice a day according to cytapheresis's realization)</description>
    <arm_group_label>Fanconi anemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plerixafor</intervention_name>
    <description>D5 : injection of 24mg/kg of plerixafor once a day until cytapheresis has be done (maximum of 4 days)</description>
    <arm_group_label>Fanconi anemia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with Fanconi anemia&#xD;
&#xD;
          -  Patient from 2 to 17 years old&#xD;
&#xD;
          -  Potential indication for allogenic bone arrow graft without HLA-identical brotherhood&#xD;
             available&#xD;
&#xD;
          -  Patient's weight &gt;10kg&#xD;
&#xD;
          -  Treated and followed for at least the previous two years in a specialized center where&#xD;
             they got a full assessment of their disease&#xD;
&#xD;
          -  For women of childbearing age, not pregnant and use of an effective contraception&#xD;
             during the entire participation in the research.&#xD;
&#xD;
          -  Affiliated or beneficiary of an health insurance regimen&#xD;
&#xD;
          -  Informed and signed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient unable to follow the visits required by the protocol&#xD;
&#xD;
          -  Positive serology for HIV-1/2, HTLV-1/2, HCV and HbS&#xD;
&#xD;
          -  Bacterial, viral, fungal or parasitic active infection with clinical signs&#xD;
&#xD;
          -  Personal history of cancer, myeloproliferative hematopathy or immune deficiency&#xD;
&#xD;
          -  Heart failure and / or heart rhythm disorder&#xD;
&#xD;
          -  History of allogeneic graft of hematopoietic stem cells&#xD;
&#xD;
          -  Patient with an HLA-identical brotherhood donor available&#xD;
&#xD;
          -  Myelodysplasia diagnose on myelogram&#xD;
&#xD;
          -  Cytogenetic abnormality on karyotype&#xD;
&#xD;
          -  Malignant solid tumor&#xD;
&#xD;
          -  Documented spontaneous genetic reversion of medullary process&#xD;
&#xD;
          -  Diagnosis of a psychiatric disorder that could compromise his/her ability to&#xD;
             participate in the study&#xD;
&#xD;
          -  Any disorder according to the investigator, that could compromise the ability of&#xD;
             patient to give his writing consent and/or to comply with requiring study's procedures&#xD;
&#xD;
          -  Current Pregnancy&#xD;
&#xD;
          -  Heart, kidney or liver failure&#xD;
&#xD;
          -  Current participation in another interventional clinical trial&#xD;
&#xD;
          -  Patient under Medical Assistance State&#xD;
&#xD;
          -  Hypersensitivity to plerixafor or any excipient contained in MOZOBIL®&#xD;
&#xD;
          -  Hypersensitivity to filgrastim or any of its' excipient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marina CAVAZZANA, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AP-HP, Necker hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital necker-Enfants malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 5, 2016</study_first_submitted>
  <study_first_submitted_qc>February 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2016</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fanconi Anemia</keyword>
  <keyword>CD34+ cells mobilization</keyword>
  <keyword>G-CSF</keyword>
  <keyword>Plerixafor</keyword>
  <keyword>gene therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fanconi Syndrome</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plerixafor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

